Abbott Laboratories Settles Investor Lawsuit Over Infant Formula Safety Claims

Abbott Laboratories (ABT) has reached a $385 million settlement in a federal court to resolve investor claims tied to safety issues at its Michigan infant formula plant. This agreement was announced last week, offering closure to litigation that had stemmed from allegations of contaminated products and undisclosed internal findings.

According to reporting shared on social media and investor discussion forums, the lawsuit originated in 2022 and focused on safety and sanitation lapses at the Sturgis, Michigan facility. The allegations claimed that Abbott knowingly sold adulterated infant formula in violation of FDA requirements, while failing to disclose contamination and inspection findings. Two separate threads on Reddit summarized the settlement, noting that it aimed to resolve these investor lawsuits tied to those claims.

Though this development has circulated in investor communities, no confirmation from Abbott’s official statements or major news outlets was located as of this writing, suggesting that further verification may emerge in coming days. Notably, one post highlighted that the Centers for Disease Control and Prevention (CDC) found no definitive link between the facility and the clinical cases under investigation.

Why This Matters for ABT Investors

If confirmed, this settlement would end a multi-year legal overhang for Abbott tied to one of its high-profile safety incidents, potentially reducing litigation risk. The resolution could help refocus investor attention on underlying operational growth in Abbott’s core medical devices, diagnostics, nutrition, and pharmaceuticals segments.

At present, Abbott shares are trading around $101.29, with a modest intraday gain of approximately 0.48%, as of September 25, 2026. This offers a snapshot of market sentiment amid the pending legal resolution.

Next Steps

• Investors should monitor Abbott’s official investor-relations site or regulatory filings for confirmation and details about the settlement.
• Analysts may revise risk profiles or re-evaluate valuation in light of litigation removal—assuming the settlement is confirmed.
• Absent official confirmation, treat this development as unverified rumor until credible sources or SEC disclosures emerge.

In summary, a $385 million settlement would represent a meaningful shift in Abbott’s legal outlook. However, until the company or reputable financial media confirm the details, investors should exercise caution in attributing any stock movement to this report.